{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:00:00Z","timestamp":1790740800511,"version":"4.1.0"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:00:00Z","timestamp":1785024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.tranon.2026.102953","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:22:19Z","timestamp":1785198139000},"page":"102953","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Lipid metabolism in \u03b3\u03b4 T-cell activation: Implications for immunotherapy in ovarian cancer"],"prefix":"10.1016","volume":"72","author":[{"given":"Karolina","family":"Stirblyte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3244-915X","authenticated-orcid":false,"given":"Yazid","family":"Ghanem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5916-5403","authenticated-orcid":false,"given":"Mark","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5850-6392","authenticated-orcid":false,"given":"Steven G.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9598-8650","authenticated-orcid":false,"given":"Feras Abu","family":"Saadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"O'Toole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"O'Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek G.","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2146-1589","authenticated-orcid":false,"given":"Bashir M.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2026.102953_bib0001","series-title":"Global Cancer Observatory: Cancer Today","author":"Ferlay","year":"2024"},{"key":"10.1016\/j.tranon.2026.102953_bib0002","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00432-025-06277-9","article-title":"Global, regional, and national burden of ovarian cancer in women aged 45+ from 1990 to 2021 and projections for 2050","volume":"151","author":"Ren","year":"2025","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102953_bib0003","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2147\/IJWH.S197604","article-title":"Ovarian cancer in the world: epidemiology and risk factors","volume":"11","author":"Momenimovahed","year":"2019","journal-title":"Int. J. Womens Health"},{"issue":"1","key":"10.1016\/j.tranon.2026.102953_bib0004","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/CEJ.0000000000000217","article-title":"Ovarian cancer: epidemiology and risk factors","volume":"26","author":"La Vecchia","year":"2017","journal-title":"Eur. J. Cancer Prev."},{"key":"10.1016\/j.tranon.2026.102953_bib0005","doi-asserted-by":"crossref","first-page":"m3773","DOI":"10.1136\/bmj.m3773","article-title":"Treatment of epithelial ovarian cancer","volume":"371","author":"Kuroki","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.tranon.2026.102953_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.577869","article-title":"Immunotherapy for ovarian cancer: adjuvant, combination, and neoadjuvant","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tranon.2026.102953_bib0007","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejcsup.2019.12.002","article-title":"Inflammation and immunity in ovarian cancer","volume":"15","author":"Salas-Benito","year":"2020","journal-title":"Eur. J. Cancer Suppl."},{"key":"10.1016\/j.tranon.2026.102953_bib0008","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00005-022-00655-8","article-title":"Immunotherapy in ovarian cancer","volume":"70","author":"Siminiak","year":"2022","journal-title":"Arch. Immunol. Ther. Exp."},{"issue":"5","key":"10.1016\/j.tranon.2026.102953_bib0009","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3390\/ijms23052847","article-title":"Challenges of the immunotherapy: perspectives and limitations of the immune checkpoint inhibitor treatment","volume":"23","author":"Dobosz","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tranon.2026.102953_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1248867","article-title":"The future of affordable cancer immunotherapy","volume":"14","author":"Schaft","year":"2023","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.tranon.2026.102953_bib0011","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.3390\/curroncol31070283","article-title":"The complex tumor microenvironment in ovarian cancer: therapeutic challenges and opportunities","volume":"31","author":"Garlisi","year":"2024","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.tranon.2026.102953_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2020.101055","article-title":"Lipids in the tumor microenvironment: from cancer progression to treatment","volume":"80","author":"Corn","year":"2020","journal-title":"Prog. Lipid Res."},{"issue":"6","key":"10.1016\/j.tranon.2026.102953_bib0013","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1085\/jgp.8.6.519","article-title":"The metabolism of tumors in the body","volume":"8","author":"Warburg","year":"1927","journal-title":"J. Gen. Physiol."},{"issue":"3","key":"10.1016\/j.tranon.2026.102953_bib0014","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ccr.2012.02.014","article-title":"Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate","volume":"21","author":"Ward","year":"2012","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.tranon.2026.102953_bib0015","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2013.05.017","article-title":"Cellular fatty acid metabolism and cancer","volume":"18","author":"Currie","year":"2013","journal-title":"Cell Metab."},{"issue":"6","key":"10.1016\/j.tranon.2026.102953_bib0016","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1242\/dmm.011338","article-title":"Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development","volume":"6","author":"Baenke","year":"2013","journal-title":"Dis. Model. Mech."},{"issue":"11","key":"10.1016\/j.tranon.2026.102953_bib0017","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.cmet.2022.09.023","article-title":"The role of lipids in cancer progression and metastasis","volume":"34","author":"Martin-Perez","year":"2022","journal-title":"Cell Metab."},{"issue":"3191","key":"10.1016\/j.tranon.2026.102953_bib0018","first-page":"309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science (1979)"},{"issue":"1","key":"10.1016\/j.tranon.2026.102953_bib0019","first-page":"1","article-title":"Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies","volume":"11","author":"Phan","year":"2014","journal-title":"Cancer Biol. Med."},{"issue":"14","key":"10.1016\/j.tranon.2026.102953_bib0020","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1073\/pnas.91.14.6379","article-title":"Fatty acid synthesis: a potential selective target for antineoplastic therapy","volume":"91","author":"Kuhajda","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.tranon.2026.102953_bib0021","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s43018-021-00183-y","article-title":"Fatty acid synthesis is required for breast cancer brain metastasis","volume":"2","author":"Ferraro","year":"2021","journal-title":"Nat. Cancer"},{"issue":"4","key":"10.1016\/j.tranon.2026.102953_bib0022","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.3390\/ijms23042170","article-title":"Fatty acid metabolism in ovarian cancer: therapeutic implications","volume":"23","author":"Yoon","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"17","key":"10.1016\/j.tranon.2026.102953_bib0023","doi-asserted-by":"crossref","first-page":"29487","DOI":"10.18632\/oncotarget.15494","article-title":"Fatty acid metabolism in breast cancer subtypes","volume":"8","author":"Monaco","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2026.102953_bib0024","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.3389\/fimmu.2018.02927","article-title":"Ovarian cancer-intrinsic fatty acid synthase prevents anti-tumor immunity by disrupting tumor-infiltrating dendritic cells","volume":"9","author":"Jiang","year":"2018","journal-title":"Front. Immunol."},{"issue":"34","key":"10.1016\/j.tranon.2026.102953_bib0025","doi-asserted-by":"crossref","first-page":"15051","DOI":"10.1073\/pnas.0910258107","article-title":"Dysregulation of the mevalonate pathway promotes transformation","volume":"107","author":"Clendening","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7","key":"10.1016\/j.tranon.2026.102953_bib0026","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/s41416-018-0270-z","article-title":"Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism","volume":"119","author":"Niemi","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"30","key":"10.1016\/j.tranon.2026.102953_bib0027","doi-asserted-by":"crossref","first-page":"47343","DOI":"10.18632\/oncotarget.10121","article-title":"Ovarian tumour growth is characterized by mevalonate pathway gene signature in an orthotopic, syngeneic model of epithelial ovarian cancer","volume":"7","author":"Greenaway","year":"2016","journal-title":"Oncotarget"},{"issue":"42","key":"10.1016\/j.tranon.2026.102953_bib0028","doi-asserted-by":"crossref","first-page":"72147","DOI":"10.18632\/oncotarget.20046","article-title":"Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer","volume":"8","author":"Kobayashi","year":"2017","journal-title":"Oncotarget"},{"issue":"60","key":"10.1016\/j.tranon.2026.102953_bib0029","doi-asserted-by":"crossref","first-page":"102912","DOI":"10.18632\/oncotarget.22076","article-title":"High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism","volume":"8","author":"Braicu","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.tranon.2026.102953_bib0030","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ijc.29010","article-title":"Large scale profiling of metabolic dysregulation in ovarian cancer","volume":"136","author":"Ke","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.tranon.2026.102953_bib0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019963","article-title":"Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer","volume":"6","author":"Fong","year":"2011","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.tranon.2026.102953_bib0032","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.cell.2020.11.009","article-title":"Obesity shapes metabolism in the tumor microenvironment to suppress anti-tumor immunity","volume":"183","author":"Ringel","year":"2020","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.tranon.2026.102953_bib0033","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1038\/nm.2492","article-title":"Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth","volume":"17","author":"Nieman","year":"2011","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.tranon.2026.102953_bib0034","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1182\/blood.2021013832","article-title":"Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins","volume":"139","author":"Panaroni","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102953_bib0035","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-023-01498-2","article-title":"Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics","volume":"16","author":"HR","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"17","key":"10.1016\/j.tranon.2026.102953_bib0036","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1038\/s41388-017-0093-z","article-title":"Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis","volume":"37","author":"Ladanyi","year":"2018","journal-title":"Oncogene"},{"issue":"21","key":"10.1016\/j.tranon.2026.102953_bib0037","first-page":"4389","article-title":"Adipocyte-induced FABP4 expression in ovarian cancer cells promotes metastasis and mediates carboplatin resistance","volume":"39","author":"Nayak","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.tranon.2026.102953_bib0038","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41419-021-03596-w","article-title":"The fatty acid receptor CD36 promotes HCC progression through activating src\/PI3K\/AKT axis-dependent aerobic glycolysis","volume":"12","author":"Luo","year":"2021","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.tranon.2026.102953_bib0039","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.cmet.2008.07.007","article-title":"SREBP activity is regulated by mTORC1 and contributes to akt-dependent cell growth","volume":"8","author":"Porstmann","year":"2008","journal-title":"Cell Metab."},{"issue":"3","key":"10.1016\/j.tranon.2026.102953_bib0040","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41423-021-00781-x","article-title":"Diet, lipids, and antitumor immunity","volume":"19","author":"Prendeville","year":"2022","journal-title":"Cell Mol. Immunol."},{"issue":"12","key":"10.1016\/j.tranon.2026.102953_bib0041","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/nrc1753","article-title":"Oncogenic PI3K deregulates transcription and translation","volume":"5","author":"Bader","year":"2005","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.tranon.2026.102953_bib0042","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1158\/1535-7163.MCT-11-0996","article-title":"The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer","volume":"11","author":"Carden","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.tranon.2026.102953_bib0043","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41590-020-00848-3","article-title":"Distinct metabolic programs established in the thymus control effector functions of \u03b3\u03b4 T cell subsets in tumor microenvironments","volume":"22","author":"Lopes","year":"2021","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.tranon.2026.102953_bib0044","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1158\/1078-0432.CCR-12-2243","article-title":"New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential","volume":"19","author":"Banerjee","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102953_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101078","article-title":"Wnt\/\u03b2-catenin signaling regulates adipose tissue lipogenesis and adipocyte-specific loss is rigorously defended by neighboring stromal-vascular cells","volume":"42","author":"Bagchi","year":"2020","journal-title":"Mol. Metab."},{"issue":"2","key":"10.1016\/j.tranon.2026.102953_bib0046","first-page":"313","article-title":"Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer","volume":"21","author":"de Lima Filho","year":"2009","journal-title":"Oncol. Rep."},{"issue":"3","key":"10.1016\/j.tranon.2026.102953_bib0047","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1158\/1541-7786.MCR-11-0177","article-title":"WNT7A regulates tumor growth and progression in ovarian cancer through the WNT\/\u03b2-catenin pathway","volume":"10","author":"Yoshioka","year":"2012","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102953_bib0048","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.gene.2018.11.098","article-title":"The role of R-spondin 1 through activating wnt\/\u03b2-catenin in the growth, survival and migration of ovarian cancer cells","volume":"689","author":"Liu","year":"2019","journal-title":"Gene"},{"issue":"2","key":"10.1016\/j.tranon.2026.102953_bib0049","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1080\/15548627.2017.1345412","article-title":"Inflammatory signaling cascades and autophagy in cancer","volume":"14","author":"Monkkonen","year":"2018","journal-title":"Autophagy"},{"issue":"3","key":"10.1016\/j.tranon.2026.102953_bib0050","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.stem.2016.11.004","article-title":"Lipid desaturation is a metabolic marker and therapeutic target of ovarian cancer stem cells","volume":"20","author":"Li","year":"2017","journal-title":"Cell Stem Cell"},{"issue":"8","key":"10.1016\/j.tranon.2026.102953_bib0051","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.4049\/jimmunol.176.8.5023","article-title":"Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype","volume":"176","author":"Hagemann","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.tranon.2026.102953_bib0052","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-3-030-49270-0_5","article-title":"\u03b3\u03b4 T cells in tumor microenvironment","volume":"1273","author":"Imbert","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"issue":"9","key":"10.1016\/j.tranon.2026.102953_bib0053","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41423-020-0504-x","article-title":"Cancer immunotherapy with \u03b3\u03b4 T cells: many paths ahead of us","volume":"17","author":"Kabelitz","year":"2020","journal-title":"Cell Mol. Immunol."},{"issue":"616","key":"10.1016\/j.tranon.2026.102953_bib0054","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj0835","article-title":"Development of ICT01, a first-in-class, anti-BTN3A antibody for activating V\u03b39V\u03b42 T cell-mediated antitumor immune response","volume":"13","author":"De Gassart","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.tranon.2026.102953_bib0055","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.3390\/cells9051206","article-title":"The role of human \u03b3\u03b4 T cells in anti-tumor immunity and their potential for cancer immunotherapy","volume":"9","author":"Liu","year":"2020","journal-title":"Cells"},{"issue":"23","key":"10.1016\/j.tranon.2026.102953_bib0056","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314797","article-title":"\u03b3\u03b4 T lymphocytes as a double-edged sword\u2014state of the art in gynecological diseases","volume":"23","author":"Paw\u0142owska","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tranon.2026.102953_bib0057","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12967-019-1897-0","article-title":"Distribution and functions of \u03b3\u03b4 T cells infiltrated in the ovarian cancer microenvironment","volume":"17","author":"Chen","year":"2019","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.tranon.2026.102953_bib0058","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1286097","article-title":"Vdelta1 T cells are more resistant than Vdelta2 T cells to the immunosuppressive properties of galectin-3","volume":"14","author":"Schadeck","year":"2024","journal-title":"Front. Immunol."},{"issue":"616","key":"10.1016\/j.tranon.2026.102953_bib0059","article-title":"Characterization of ascites- and tumor-infiltrating \u03b3\u03b4 T cells reveals distinct repertoires and a beneficial role in ovarian cancer","volume":"13","author":"Foord","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tranon.2026.102953_bib0060","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12943-023-01722-0","article-title":"Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment","volume":"22","author":"Gao","year":"2023","journal-title":"Mol. Cancer"},{"issue":"11","key":"10.1016\/j.tranon.2026.102953_bib0061","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/ni.2713","article-title":"CD1d-lipid antigen recognition by the \u03b3\u03b4 TCR","volume":"14","author":"Uldrich","year":"2013","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.tranon.2026.102953_bib0062","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3390\/cells11060964","article-title":"Tissue-specific expression of TIGIT, PD-1, TIM-3, and CD39 by \u03b3\u03b4 T cells in ovarian cancer","volume":"11","author":"Weimer","year":"2022","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.tranon.2026.102953_bib0063","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1007\/s00262-020-02638-0","article-title":"TIM-3 blockade combined with bispecific antibody MT110 enhances the anti-tumor effect of \u03b3\u03b4 T cells","volume":"69","author":"Guo","year":"2020","journal-title":"Cancer Immunol. Immunther."},{"issue":"34","key":"10.1016\/j.tranon.2026.102953_bib0064","doi-asserted-by":"crossref","first-page":"E3562","DOI":"10.1073\/pnas.1403424111","article-title":"Murine CD27(-) V\u03b36(+) \u03b3\u03b4 T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages","volume":"111","author":"Rei","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"12","key":"10.1016\/j.tranon.2026.102953_bib0065","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nri.2017.101","article-title":"\u03b3\u03b4 T cells in homeostasis and host defence of epithelial barrier tissues","volume":"17","author":"Nielsen","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.tranon.2026.102953_bib0066","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41589-022-01017-3","article-title":"Lipid metabolism in T cell signaling and function","volume":"18","author":"Lim","year":"2022","journal-title":"Nat. Chem. Biol."},{"issue":"8","key":"10.1016\/j.tranon.2026.102953_bib0067","doi-asserted-by":"crossref","first-page":"4670","DOI":"10.4049\/jimmunol.174.8.4670","article-title":"Glucose availability regulates IFN-\u03b3 production and p70S6 kinase activation in CD8+ effector T cells","volume":"174","author":"Cham","year":"2005","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.tranon.2026.102953_bib0068","first-page":"1620","article-title":"Adenosine pathway orchestrates immunosuppressive microenvironment and impacts \u03b3\u03b4 T cell function in ovarian cancer","volume":"11","author":"Wang","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.tranon.2026.102953_bib0069","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12943-017-0665-0","article-title":"Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma","volume":"16","author":"Ma","year":"2017","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2026.102953_bib0070","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imr.12528","article-title":"The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets","volume":"276","author":"Allard","year":"2017","journal-title":"Immunol. Rev."},{"issue":"12","key":"10.1016\/j.tranon.2026.102953_bib0071","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nrc.2017.86","article-title":"Targeting immunosuppressive adenosine in cancer","volume":"17","author":"Vijayan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.tranon.2026.102953_bib0072","first-page":"129","article-title":"Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion","volume":"6","author":"H\u00e4usler","year":"2014","journal-title":"Am. J. Transl. Res."},{"issue":"6","key":"10.1016\/j.tranon.2026.102953_bib0073","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/JLB.3MA0420-278RR","article-title":"Identification of a regulatory V\u03b41 gamma delta T cell subpopulation expressing CD73 in human breast cancer","volume":"107","author":"Chabab","year":"2020","journal-title":"J. Leukoc. Biol."},{"issue":"3","key":"10.1016\/j.tranon.2026.102953_bib0074","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ccell.2016.06.025","article-title":"Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses","volume":"30","author":"Young","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tranon.2026.102953_bib0075","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3389\/fimmu.2019.00925","article-title":"Targeting adenosine in cancer immunotherapy to enhance T-cell function","volume":"10","author":"Vigano","year":"2019","journal-title":"Front. Immunol."},{"issue":"35","key":"10.1016\/j.tranon.2026.102953_bib0076","doi-asserted-by":"crossref","first-page":"13132","DOI":"10.1073\/pnas.0605251103","article-title":"A2A adenosine receptor protects tumors from antitumor T cells","volume":"103","author":"Ohta","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.tranon.2026.102953_bib0077","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4049\/jimmunol.1101845","article-title":"Adenosine A2B receptor blockade slows growth of bladder and breast tumors","volume":"188","author":"Cekic","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.tranon.2026.102953_bib0078","article-title":"Metabolic reprogramming and prognostic insights in molecular landscapes driven by glycolysis in ovarian cancer","volume":"15","author":"Wang","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tranon.2026.102953_bib0079","series-title":"ICT01 Granted FDA Breakthrough Therapy Designation for Frontline AML Indication [press release]","year":"2026"},{"key":"10.1016\/j.tranon.2026.102953_bib0080","article-title":"A close look at current \u03b3\u03b4 T-cell immunotherapy","volume":"14","author":"Ma","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tranon.2026.102953_bib0081","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12929-022-00866-3","article-title":"Tumor microenvironment: barrier or opportunity towards effective cancer therapy","volume":"29","author":"Tiwari","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.tranon.2026.102953_bib0082","first-page":"31","article-title":"Nanoparticle-mediated lipid metabolic reprogramming of T cells in tumor microenvironments for immunometabolic therapy","volume":"13","author":"Kim","year":"2021","journal-title":"Nanomicro Lett."},{"key":"10.1016\/j.tranon.2026.102953_bib0083","first-page":"400","article-title":"Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy","volume":"21","author":"Kiaie","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.tranon.2026.102953_bib0084","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.840440","article-title":"Lipid metabolism regulation based on nanotechnology for enhancement of tumor immunity","volume":"13","author":"Tu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tranon.2026.102953_bib0085","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.3389\/fphar.2018.01154","article-title":"Reconstituted HDL: drug delivery platform for overcoming biological barriers to cancer therapy","volume":"9","author":"Raut","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tranon.2026.102953_bib0086","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.138960","article-title":"Immunomodulatory and anti-ovarian cancer effects of novel astragalus polysaccharide micelles loaded with podophyllotoxin","volume":"290","author":"Liu","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"7","key":"10.1016\/j.tranon.2026.102953_bib0087","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.immuni.2021.05.003","article-title":"Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors","volume":"54","author":"Xu","year":"2021","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.tranon.2026.102953_bib0088","first-page":"236","article-title":"Helios, CD73 and CD39 induction in regulatory T cells exposed to adipose derived mesenchymal stem cells","volume":"22","author":"Fakhimi","year":"2020","journal-title":"Cell J."},{"key":"10.1016\/j.tranon.2026.102953_bib0089","article-title":"Visual analysis of ovarian cancer immunotherapy: a bibliometric analysis from 2014 to 2024","volume":"12","author":"Xu","year":"2025","journal-title":"Front. Med."},{"issue":"12","key":"10.1016\/j.tranon.2026.102953_bib0090","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.3390\/cancers15123220","article-title":"Chasing immune checkpoint inhibitors in ovarian cancer: novel combinations and biomarker discovery","volume":"15","author":"Colombo","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tranon.2026.102953_bib0091","series-title":"A Study of Ciforadenant in Combination with Chemotherapy in Patients with Ovarian Cancer [Internet]","year":"2023"},{"key":"10.1016\/j.tranon.2026.102953_bib0093","unstructured":"Ipsen U.S. FDA grants Ipsen's IPN60340 (ICT01) Breakthrough Therapy Designation in first-line unfit acute myeloid leukemia. Press release. January 13, 2026. https:\/\/www.ipsen.com\/press-release\/u-s-fda-grants-ipsens-ipn60340-ict01-breakthrough-therapy-designation-in-first-line-unfit-acute-myeloid-leukemia-3218133\/."},{"issue":"616","key":"10.1016\/j.tranon.2026.102953_bib0094","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj0835","article-title":"Development of ICT01, a first-in-class, anti-BTN3A antibody for activating V\u03b39V\u03b42 T cell-mediated antitumor immune response","volume":"13","author":"De Gassart","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.tranon.2026.102953_bib0095","article-title":"Adoptive transfer of engineered \u03b3\u03b4 T cells for cancer immunotherapy","volume":"10","author":"Kedia","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tranon.2026.102953_bib0096","article-title":"CAR-\u03b3\u03b4 T cells for solid tumors: challenges and opportunities","volume":"14","author":"Lamb","year":"2023","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.tranon.2026.102953_bib0097","first-page":"567","article-title":"Metabolic engineering of T cells for enhanced anti-tumor function","volume":"22","author":"Zhang","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.tranon.2026.102953_bib0098","first-page":"234","article-title":"CPT1A overexpression enhances T cell persistence in lipid-rich environments","volume":"35","author":"Chen","year":"2023","journal-title":"Cell Metab."},{"issue":"5","key":"10.1016\/j.tranon.2026.102953_bib0099","first-page":"456","article-title":"TME-restricted nanoparticle delivery systems for cancer immunotherapy","volume":"18","author":"Wang","year":"2023","journal-title":"Nat. Nanotechnol."},{"issue":"2","key":"10.1016\/j.tranon.2026.102953_bib0100","first-page":"234","article-title":"CPT1A overexpression enhances T cell persistence in lipid-rich environments","volume":"35","author":"Chen","year":"2023","journal-title":"Cell Metab."},{"issue":"5","key":"10.1016\/j.tranon.2026.102953_bib0101","first-page":"456","article-title":"TME-restricted nanoparticle delivery systems for cancer immunotherapy","volume":"18","author":"Wang","year":"2023","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.tranon.2026.102953_bib0102","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.840440","article-title":"Lipid metabolism regulation based on nanotechnology for enhancement of tumor immunity","volume":"13","author":"Tu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tranon.2026.102953_bib0103","series-title":"A Study of Ciforadenant in Combination with Chemotherapy in Patients with Ovarian Cancer [Internet]","year":"2023"},{"issue":"1","key":"10.1016\/j.tranon.2026.102953_bib0104","article-title":"Metabolic targeting of \u03b3\u03b4 T cells in the tumor microenvironment","volume":"12","author":"Noman","year":"2023","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.tranon.2026.102953_bib0105","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41573-019-0038-z","article-title":"Translating gammadelta (\u03b3\u03b4) T cells and their receptors into cancer cell therapies","volume":"19","author":"Sebestyen","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.tranon.2026.102953_bib0106","first-page":"12345","article-title":"Nanoparticle delivery of immunomodulatory agents for cancer therapy","volume":"16","author":"Park","year":"2022","journal-title":"ACS Nano"},{"issue":"2","key":"10.1016\/j.tranon.2026.102953_bib0107","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tranon.2026.102953_bib0108","first-page":"567","article-title":"FASN inhibition in cancer therapy: challenges and opportunities","volume":"12","author":"Liu","year":"2021","journal-title":"Cell Death Dis."},{"issue":"11","key":"10.1016\/j.tranon.2026.102953_bib0109","article-title":"CD36 as a target for metabolic modulation in cancer","volume":"1866","author":"Glatz","year":"2021","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"issue":"15","key":"10.1016\/j.tranon.2026.102953_bib0110","article-title":"TME-restricted nanoparticle delivery systems for cancer immunotherapy","volume":"34","author":"Sun","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.tranon.2026.102953_bib0111","first-page":"876","article-title":"PPAR\u03b1 agonist-loaded nanoparticles for metabolic reprogramming of T cells in the tumor microenvironment","volume":"348","author":"Li","year":"2022","journal-title":"J. Control Release"},{"key":"10.1016\/j.tranon.2026.102953_bib0112","article-title":"FASN inhibition combined with PD-1 blockade for ovarian cancer immunotherapy","volume":"289","author":"Zhang","year":"2022","journal-title":"Biomaterials"},{"issue":"15","key":"10.1016\/j.tranon.2026.102953_bib0113","article-title":"A2AR antagonist-loaded nanoparticles for adenosine pathway inhibition in cancer immunotherapy","volume":"18","author":"Chen","year":"2022","journal-title":"Small"},{"key":"10.1016\/j.tranon.2026.102953_bib0114","first-page":"4261","article-title":"Combination of A2AR antagonist and CD36 inhibitor for enhanced anti-tumor immunity","volume":"13","author":"Yang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2026.102953_bib0115","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1038\/s41467-022-31926-9","article-title":"Nanoparticle-mediated co-delivery of metabolic modulators and checkpoint inhibitors for cancer immunotherapy","volume":"13","author":"Reda","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.tranon.2026.102953_bib0116","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cmet.2019.04.002","article-title":"Cholesterol induces CD8+ T-cell exhaustion in the tumor microenvironment","volume":"30","author":"Ma","year":"2019","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.tranon.2026.102953_bib0117","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nri.2017.76","article-title":"Single-cell RNA sequencing to explore immune cell heterogeneity","volume":"18","author":"Papalexi","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tranon.2026.102953_bib0118","first-page":"45","article-title":"CRISPR-Cas9 screening identifies LXR as a regulator of T cell exhaustion","volume":"8","author":"Wei","year":"2022","journal-title":"Cell Discov."},{"issue":"4","key":"10.1016\/j.tranon.2026.102953_bib0119","article-title":"A2AR activation promotes CD36 expression and lipid accumulation in T cells","volume":"218","author":"Huang","year":"2021","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.tranon.2026.102953_bib0120","first-page":"143","article-title":"CAR-T cell engineering for metabolic fitness in the tumor microenvironment","volume":"29","author":"Lynn","year":"2023","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.tranon.2026.102953_bib0121","first-page":"789","article-title":"CD36 deletion enhances CAR-T cell persistence in lipid-rich tumors","volume":"40","author":"Ma","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tranon.2026.102953_bib0122","first-page":"245","article-title":"Intraperitoneal versus intravenous nanoparticle delivery in ovarian cancer models","volume":"326","author":"Patel","year":"2020","journal-title":"J. Control Release"},{"issue":"8","key":"10.1016\/j.tranon.2026.102953_bib0123","first-page":"831","article-title":"TME-targeted nanoparticle delivery systems for cancer immunotherapy","volume":"18","author":"Shi","year":"2023","journal-title":"Nat. Nanotechnol."},{"issue":"6","key":"10.1016\/j.tranon.2026.102953_bib0124","article-title":"Metabolic vulnerabilities of \u03b3\u03b4 T cell subsets in ovarian cancer","volume":"4","author":"Wang","year":"2023","journal-title":"Cell Rep. Med."},{"issue":"6","key":"10.1016\/j.tranon.2026.102953_bib0125","first-page":"1234","article-title":"Lipid metabolism and immune cell function in the tumor microenvironment","volume":"56","author":"Zhang","year":"2023","journal-title":"Immunity"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326002895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326002895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:30:35Z","timestamp":1790739035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326002895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":124,"alternative-id":["S1936523326002895"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102953","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid metabolism in \u03b3\u03b4 T-cell activation: Implications for immunotherapy in ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102953","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102953"}}